Yahoo
NasdaqGM - Nasdaq Real Time Price USD

TransMedics Group, Inc. (TMDX)

84.87 +15.89 (+23.04%)
As of 12:37:54 PM EST. Market Open.
Trade TMDX on Coinbase
TMDX Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for TMDX
  • Previous Close 68.98
  • Open 78.71
  • Bid 55.39 x 200
  • Ask 87.47 x 200
  • Day's Range 76.50 - 85.78
  • 52 Week Range 60.10 - 156.00
  • Volume 1,474,901
  • Avg. Volume 811,539
  • Market Cap (intraday) 2.943B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 21.99
  • EPS (TTM) 3.86
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 98.73
  • Zacks Rating Neutral

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com

898

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TMDX
30.23%
S&P 500 (^GSPC)
7.84%

1-Year Return

TMDX
32.09%
S&P 500 (^GSPC)
9.85%

3-Year Return

TMDX
111.17%
S&P 500 (^GSPC)
69.08%

5-Year Return

TMDX
169.51%
S&P 500 (^GSPC)
57.15%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 203M
Earnings 17.07M
Profit Margin 8.41%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
200M
20.0%
40.0%
60.0%

Analyst Insights

View More

Analyst Price Targets

65.00 Low
98.73 Average
84.87 Current
125.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 95 -> 94

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.85%

  • Return on Assets (ttm)

    4.39%

  • Return on Equity (ttm)

    31.89%

  • Revenue (ttm)

    727.65M

  • Net Income Avi to Common (ttm)

    144.45M

  • Diluted EPS (ttm)

    3.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    492.96M

  • Total Debt/Equity (mrq)

    157.41%

  • Levered Free Cash Flow (ttm)

    18.24M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: